NCT04020705View on ClinicalTrials.gov

The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma

NACompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 22, 2015

Primary Completion Date

March 19, 2019

Study Completion Date

March 19, 2019

Conditions
Glaucoma
Interventions
DEVICE

Citicoline eye drops (OMK1)

(OMK1) will be prescribed in the dosage of 1 drop 3 times a day

OTHER

Placebo Comparator: hypromellose based ocular lubricant

will be prescribed in the dosage of 1 drop 3 times a day

All Listed Sponsors
collaborator

University of Milan

OTHER

lead

Istituto di Ricerca Neuroftalmologia S.r.l.

NETWORK

NCT04020705 - The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma | Biotech Hunter | Biotech Hunter